10-K: PharmaCyte Biotech Reports Fiscal Year 2024 Results Amidst Strategic Review and Clinical Hold

PharmaCyte Biotech's annual report reveals a year of strategic reevaluation, reduced spending, and ongoing efforts to address an FDA clinical hold on its pancreatic cancer therapy.

Summary

• PharmaCyte Biotech, a biotechnology company focused on developing cellular therapies for cancer, reported its fiscal year 2024 results.
• The company is currently focused on its Cell-in-a-Box technology, particularly for locally advanced, inoperable pancreatic cancer (LAPC).
• Research and development in the treatment of diabetes has been discontinued.
• The company is undergoing a strategic review of its programs and relationship with SG Austria, including the fact that all licensed patents have expired and that know-how relating to its Cell-in-a-Box technology solely resides with SG Austria.
• Spending on development programs has been reduced until the review is complete.
• The company is reevaluating programs dependent on SG Austria and the FDA's acceptance of its technologies, including its LAPC program.
• The FDA placed the company's Investigational New Drug Application (IND) on clinical hold in October 2020.
• The company has completed stability studies on its clinical trial product candidate and cells from its Master Cell Bank (MCB).
• The company has also completed various additional studies requested by the FDA, including biocompatibility and systemic toxicity testing.
• The company is in the process of providing data to the FDA to address the clinical hold.
• The company had two full-time employees and several consultants as of April 30, 2024.
• The company reported a net loss attributable to common stockholders of approximately $17.2 million for the year ended April 30, 2024, compared to $4.3 million for the year ended April 30, 2023.
• As of April 30, 2024, the company had an accumulated deficit of approximately $115.6 million.
• The company had cash and cash equivalents of approximately $50.2 million as of April 30, 2024, compared to approximately $68 million as of April 30, 2023.

Sentiment

Score: 3

Explanation: The document presents a challenging situation for the company, with significant losses, a clinical hold, and a strategic review underway. While the company has completed some studies, the overall outlook is uncertain and requires significant improvements to achieve success.

Positives

• The company has successfully completed stability studies on its clinical trial product candidate and cells from its Master Cell Bank.
• The company has completed various additional studies requested by the FDA, including biocompatibility and systemic toxicity testing.
• The company is actively working to address the FDA's concerns and lift the clinical hold on its IND.
• The company has cash and cash equivalents of approximately $50.2 million as of April 30, 2024.

Negatives

• The company is undergoing a strategic review of its programs and relationship with SG Austria.
• The company has reduced spending on development programs until the review is complete.
• The company is reevaluating programs dependent on SG Austria and the FDA's acceptance of its technologies.
• The company's IND for a planned clinical trial in LAPC remains on clinical hold.
• The company reported a net loss attributable to common stockholders of approximately $17.2 million for the year ended April 30, 2024.
• The company has an accumulated deficit of approximately $115.6 million as of April 30, 2024.

Risks

• The company's future success is dependent on its ability to successfully address the FDA's clinical hold.
• The company's reliance on Austrianova for manufacturing increases the risk of insufficient product quantities or unacceptable costs.
• Disruptions in the global economy and supply chains may have a material adverse effect on the company's business.
• The company may not be able to raise sufficient capital to fund its future clinical trials and product development.
• The company may not be able to protect its intellectual property rights throughout the world.
• The company may experience volatility in its stock price.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues its research and development of its product candidates.

Management Comments

• The Board has reduced spending on our programs, including pre-clinical and clinical activities, until the review by the Scientific Committee and the Board is complete and the Board has determined the actions and plans to be implemented.
• The Scientific Committees recommendations will include potentially seeking a new framework for our relationship with SG Austria and its subsidiaries.

Industry Context

The company operates in the competitive biotechnology industry, facing competition from major pharmaceutical companies, specialty pharmaceutical companies, and other biotechnology companies, as well as academic institutions and research organizations.

Comparison to Industry Standards

• The company's reliance on a single manufacturer, Austrianova, is a common risk for early-stage biotech companies, but the lack of identified alternatives is a concern.
• The company's ongoing strategic review and reduced spending are not uncommon for companies facing regulatory hurdles and financial constraints.
• The company's net loss and accumulated deficit are typical for development-stage biotech companies with no approved products.
• The company's cash position of $50.2 million is relatively low compared to other companies in the sector, which may limit its ability to fund future clinical trials and product development.

Management Changes

Corporate Governance

Legal Proceedings

• On December 4, 2023, H.C. Wainwright & Co., LLC filed a complaint against the company for breach of contract, seeking damages of not less than $1,950,000 and warrants to purchase 656,250 shares of common stock.
• The company intends to vigorously defend against the complaint and does not believe that any potential loss is reasonably probable at this time.

Related Party Transactions

• The company purchased products and services from SG Austria subsidiaries in the approximate amounts of $0 and $339,000 in the years ended April 30, 2024, and 2023, respectively.
• The company paid Vin-de-Bona approximately $5,000 and $61,000 for consulting services in the years ended April 30, 2024, and 2023, respectively.

Stakeholder Impact

• Shareholders may experience further dilution as a result of future equity offerings.
• Employees may be affected by the company's reduced spending and strategic review.
• Customers and partners may experience delays in the company's development programs.
• Creditors may be affected by the company's financial challenges.

Next Steps

• The company will complete the review by the Scientific Committee and the Board.
• The company will seek a new framework for its relationship with SG Austria and its subsidiaries.
• The company will continue to work to address the FDA's concerns and lift the clinical hold on its IND.
• The company will continue to evaluate its programs and prioritize development of certain product candidates.

Key Dates

Keywords

Cell-in-a-Box, pancreatic cancer, clinical hold, FDA, biotechnology, cellular therapies, SG Austria, Austrianova, CypCaps, IND